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ABSTRACT

Wang, Jinju. M.S., Department of Pharmacology and Toxicology, Wright State
University, 2011.
Differentiation of Megakaryocytes/Platelets and Neurons from Human
Endometrial Stromal Progenitor Cells.1

1

human endometrium is a high dynamic tissue that contains stem/progenitor

cells. These endometrial stromal progenitor cells (hESCs) have been
differentiated into a number of mesodermal lineages. There is limited information
on differentiating hESCs into neurons, and no information on differentiating
hESCs into megakaryocytes (MKs) and platelets (PLTs). The aim of this work
was to investigate the possibility of differentiating hESCs into two distinct
lineages: MKs, with subsequent PLT formation, and neurons.
We isolated hESCs from human endometrial tissue and cultured the cells for 4-6
passages. Before each differentiation experiment, the purity of hESCs was
confirmed by flow cytometry analysis which revealed that the cells were highly
positive (>95%) for CD90 and CD29 (stromal cell markers), and were negative
(<1.3%) for CD45 and CD34 (hematopoietic cell markers).
For MKs differentiation, hESCs (1.8×105 cells/well) were cultured in serum-free
medium either with (differentiation) or without (control) thrombopoietin (TPO, 50
ng/ml) for 18 days. MKs differentiation was analyzed by flow cytometry and
confocal microscopy. PLTs were collected from culture medium supernatant from
day10-18, and were defined by flow cytometry and functional study. Our results
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show: 1) MKs were successfully generated as evidenced by expression of MK
membrane markers (CD41a: 39 ± 3.0% and 1 ± 0.09%; CD42b: 28 ± 2.0% and
1.2 ± 0.06%, differentiation vs. control, n=3). 2) Immunocytochemistry analysis
showed the differentiation rate of CD41a (38 ± 3.0%) and CD42b (27 ± 2.5%). 3)
Generated PLTs were positively labeled with CD41a (90 ± 2%). 4) Functional
study of generated PLTs revealed that thrombin (5 U/ml) stimulation up-regulated
CD62P expression (26.0 ± 4% and 2.5 ± 1%, thrombin vs. control, n=3), and
fibrinogen binding (32 ± 3.0% and 1 ± 0.4%, thrombin vs. control, n=3). 5)
Electronic microscopic examination showed that generated PLTs had similar
ultrastructure (storage granules) as normal human peripheral blood PLTs.
For neuron differentiation, hESCs (1.6×105 cells/well) were cultured in medium
either with (differentiation) or without (control) cytokines (FGF, EGF, NGF and
BDNF) for 14 days. Differentiated neurons were analyzed by confocal
microscopy and western blot analysis. Our results show: 1) neurons were
successfully generated as evidenced by phenotypic expression of neuron
specific markers nestin (40 ± 4%), β-tublin III (37 ± 3%), NeuN (15 ± 2%), TH (14
± 1%), and astrocyte marker GFAP (10 ± 3%). 2) Western blot analysis showed
that the expression of transcription genes (Oct4: 0.11 ± 0.01and 0.32 ± 0.01;
Sox2: 0.25 ± 0.02 and 0.52 ± 0.03, differentiated vs. control, n=4) was downregulated in differentiated neurons.
Taken together, these data indicate that it’s feasible to generate MKs, functional
PLTs and neurons from hESCs. The hESCs could be a potential source for cellbased therapy in regenerative medicine.
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I. INTRODUCTION AND PURPOSE
Structure of Human Endometrium
The endometrium, or uterine mucosa, presents the most inner layer of the uterine
wall. It is comprised of an epithelial lining and underlying stroma. The surface
(simple columnar) epithelial cells that line the uterine cavity are situated on a
basement membrane. Deep to the surface epithelium are glands that extend the
full thickness of the mucosa. The glands are separated from each other by a
highly cellular connective tissue. Deep to the stroma is the muscular myometrium,
which forms the middle and outer uterine wall.
The endometrium is structurally and functionally divided into two major zones,
the upper functionalis layer and the lower basalis layer (Gargett, 2007) (Fig1).
The functionalis layer is shed at menstruation and is subsequently regenerated
each month from putative progenitor cells located in the remaining basalis zone
(Padykula, 1991).
Endometrium of reproductive-age females is highly dynamic. It has a remarkable
capacity for self-renewal, undergoing more than 400 complete cycles of
regeneration, differentiation and shedding during the reproductive years (Gargett
et al, 2008). After the endometrium is shed as part of the physiologic, normal 28day menstrual cycle, it regenerates to a thickness of 4-7 mm within 4-10 days
(McLennan & Rydell, 1965). The regenerative capacity of human endometrium is
believed to be at least equivalent to many highly regenerative organs, such as
epidermis, intestinal epithelium and bone marrow, where adult stem cells
1	
  
	
  

	
  

replenish lost cells to maintain tissue homeostasis (Fuchs & Segre, 2000;Li & Xie,
2005).

Fig 1. Diagram demonstrating the histologic structure of human endometrium.
The endometrium is divided into two major zones: upper functionalis and

lower basalis layers (Adapted from Gargett et al., 2007).

Presence of Stromal Progenitor Cells in Human Endometrium
The hypothesis that the regenerative ability of endometrium is mediated by adult
stem cells or a progenitor cell population was proposed more than two decades
ago. It was based on the evidence from histological studies of human and
primate endometrium (Padykula et al, 1984; Padykula, 1991; Prianishnikov,
1978). However, initial evidence for stem/progenitor cells activity in human
2	
  
	
  

	
  

endometrium was not reported until 2004. In that year, Chan and coworkers
isolated stromal and epithelial stem cells exhibiting a high proliferative potential
(Chan et al, 2004). Later, the same group identified the clonogenic epithelial and
stromal cells in active, cycling and inactive endometrium (Schwab et al, 2005).
Further evidence included that endometrial stromal cells are able to differentiate
into multiple cell lineages. Wolff et al found that only the endometrial stromal cells
can be differentiated into chondrocytes in a defined medium, as compared with
other monolayer cells generated from myometrial, fibroid, fallopiantube, and
uterosacral ligament tissue (Wolff et al, 2007). Most recently, The Dimitrov group
reported that human endometrial stromal progenitor cells (hESCs) can be
cultured for more than 15 passages and showed high clonogenic efficiency (15%)
(Dimitrov et al, 2008). Gargett et al described that single endometrial stromal cell
can form cellular colonies that can be further serially cloned. Further, it was
shown that cloned stromal cells can be differentiated into mesodermal lineages
including adipogenic, osteogenic, myogenic and chondrogenic cells in the
presence of corresponding inducing factors (Gargett et al, 2009). Taken together,
these findings strongly indicate that multipotent stromal stem/progenitor cells
exist in human endometrium. The putative location of these cells is near blood
vessels in the basalis layer of endometrium (Gargett, 2007;Schwab et al, 2005)
(Fig 2). 	
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Fig 2. Diagram illustrating putative location of endometrial stem/progenitor

cells. Dotted line designates separation between the functionalis and basal
layers. Progenitor cells are located in the basal layer, near blood vessels
(Adapted from Gargett et al., 2007).

	
  

Menorrhagia: a Common Bleeding Disorder in Reproductive-age Females
Menorrhagia is defined as excessively heavy uterine bleeding during normal
menstrual cycle intervals and corresponds in adult females to more than 80mL of
blood loss per menstrual period. It is common among women of reproductive
ages. Women with menorrhagia may experience diminished quality of life
parameters, psychosocial issues in addition to developing anemia, diminished
reproductive capacity and untoward pregnancy complications. It also places
women with this disorder at an increased risk of having unnecessary
hysterectomies and other gynecological procedures (Gould, 1995;Hickey &
Fraser, 1995). Indeed, one-third women in the United States have
hysterectomies before the age of 60 years and menorrhagia is the main
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presenting problem in at least one-half of these women. Approximately one-half
of women who have a hysterectomy for menorrhagia are found to have an
anatomically normal uterus indicating that other causes are responsible for the
heavy uterine bleeding (Duckitt & Collins, 2008).
Menorrhagia is a common symptom of von Willebrand disease (vWD) in adult
presenting with menorrhagia (Lusher, 1996). Recent studies have demonstrated
that menorrhagia also is prevalent in adolescent girls with inherited bleeding
disorders, particularly in those with PLT function disorders (PFDs) (Chi et al,
2010;El-Hemaidi et al, 2007;Hossain et al, 2010). PFDs are inherited
heterogeneous disorders. The most common PFD subtype, dense granule
storage pool deficiency, is a heterogeneous disorder and is frequently found
among patients with mild to moderate bleeding diatheses that do not have vWD.
Because PLT dense granules contain proaggregation factors for the formation of
a haemostatic plug, the overall consequence of poor PLT plug formation result in
clinical bleeding disorders, of which menorrhagia is a common problem. Patients
with the PFD subtype dense granule storage pool deficiency that experience
menorrhagia refractory to medical therapy are in some cases treated with PLT
transfusions. One objective of the thesis is to use ex vivo methods to generate
MKs and PLTs from human endometrial stem/progenitor cells. The overall aim is
to then evaluate them for use as a novel therapeutic modality in the treatment of
menorrhagia in both adult and adolescent females, from all ethnic-ancestral
backgrounds, with menorrhagia and documented platelet storage pool (dense
granule) defects. If PLTs with normal dense granules can be generated from
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patients in an in vitro culture system, it will represent an important first step in
using the patients’ own stem cells as a source of PLTs for autotransplantation or
allotransplantation to treat PLT disorders.

MKs and PLTs
MKs are myeloid cells (constituting less than 1% of these cells) that reside
primarily in the bone marrow (BM), and undergo a series of dynamic changes to
become mature MKs (Nurden et al, 1997). Importantly, MKs are PLT precursor
cells. Mature MKs are characterized morphologically by their large cell size,
abundant cytoplasm, the presence of numerous intracellular granules and a
distinctive demarcation membrane system (DMS). The DMS was originally
thought to divide the MK cytoplasm into small fields where individual PLT would
assemble to subsequently be released. PLTs are terminally differentiated cells
that represent non-nucleated fragments of the MKs. PLTs have multifactorial
roles. They are known to play a key role in haemostatic plug formation (VargaSzabo et al, 2008). They also participate in arterial thrombosis (Davi & Patrono,
2007), the innate immune response and metastatic tumor cell biology
(Kaushansky, 2009;van der Meer & Pietersz, 2005). PLTs circulate in the blood
for a short life span of 7-10 days and need to be replaced in order to maintain
normal levels in the blood (Hartwig & Italiano, Jr., 2003). The circulating
concentration of PLTs is around 1.5 - 4.5 x 1011 per liter of blood in a healthy
individual. The circulating PLT level is regulated by both PLT production and
destruction. Megakaryocytopoiesis and thrombopoiesis are two essential
6	
  
	
  

	
  

processes involved in PLT production (Kuter et al, 2001). Megakaryocytopoiesis
starts with hematopoietic stem cells (HSCs) that undergo lineage commitment,
proliferation and differentiation, all of which are regulated by various cytokines
and growth factors. Thrombopoiesis is involved in the process of releasing
functional PLTs into the circulation. Abnormalities in these processes can result
in clinical bleeding disorders. For example, menorrhagia due to PLT disorders
can be caused by either PLT deficiency (thrombocytopenia) or PLT dysfunction.
PLT transfusion is widely used for treatment of various PLT-related diseases,
such as thrombocytopenia and in cases of menorrhagia that are refactory to
medical therapy (Blumberg et al, 2008;Kanbur et al, 2003;Nevo et al,
2007;Stephan et al, 1999). In the United States, the total number of PLT
transfusions is over 10 million units per year and is increasing annually. This
steady increase in demand challenges the US blood transfusion community.
Moreover, the short storage life of PLT concentrates, the risk of pathogenic
contamination, and the variability of quality and quantity of the donor-derived
PLTs compromise the supply of PLTs from traditional donor-dependent method
of harvesting PLTs (Matsunaga et al, 2006;Stevens et al, 2006). Thus, the
search for developing an alternative approach to produce large numbers of PLTs
is intensely appealing. To this end, producing PLTs from stem cells holds great
promise as an alternative approach.
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Generation of MKs and PLTs from Stem Cells in vitro
Thrombopoietin (TPO), also known as c-Mpl ligand, is a growth factor and a key
physiological regulatory factor that induces MK proliferation and maturation
(Alexander et al, 1996;Gurney et al, 1994;Kaushansky et al, 1994;Kaushansky,
1995). The in vitro use of TPO renders possible the generation of highly enriched
MKs with normal structural features and function. Production of PLTs in vitro also
has been attempted with the goal of using them for transfusions in patients with
PLT disorders. Choi et al first demonstrated the feasibility of in vitro generation of
functional PLTs by stimulating the release of PLTs from cultured MKs
differentiated from human peripheral blood (Choi et al, 1995). After that, other
investigators have successfully produced MKs and PLTs in vitro from HSCs and
embryonic stem cells (Eto et al, 2002;Fujimoto et al, 2003;Gaur et al,
2006;Matsunaga et al, 2006;Takayama et al, 2008), as well as from progenitors
of subcutaneous adipose tissue (Matsubara et al, 2009). The culture-derived
PLTs exhibit similar features to PLTs from peripheral blood with respect to
morphology and function. Chen et al reported that transplantation of generated
MKs can accelerate the recovery of MKs and PLTs and reduce
thrombocytopenia in mice model (Chen et al, 2009). Furthermore, some clinical
trials have shown transplantation of in vitro expanded MK progenitors into
patients can boost PLTs recovery (Bertolini et al, 1997; Matsunaga et al, 2006;
Paquette et al, 2000; Scheding et al, 2004). Groups led by Eto and Fujimoto
developed approaches to generate a large amount of PLTs in vitro from murine
embryonic stem cells (Eto et al, 2002; Fujimoto et al, 2003). Currently, no one
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has reported on MK and PLT production from human endometrial-derived stem
cells.

Ischemic Stroke and Neuron Stem Cells
Stroke can cause permanent neurological damage and are associated with many
complications. It is one of the leading causes of death and disability worldwide
and has an incidence of approximately 150-200 in 100,000 (Modan & Wagener,
1992). There are 2 types of stroke: ischemic stroke and hemorrhagic stroke.
Ischemic stroke is caused by occlusion of a blood vessel in the brain and
constitutes the majority of stroke cases (85-90%) (Qureshi et al, 2001).
Neurons are the core components of the nervous system. They are electrically
excitable cells that process and transmit information to the central nervous
systems via various electrical and chemical mechanisms. The nerve system has
a limited capacity for self repair owing to the lack of mature neurons to undergo
cell division. In most cases, mature neurons are regenerated by adult neural
stem cells, which are found mainly in 2 regions in brain: subventricular zone
(SVZ) of the lateral ventricles (LV) and subgranular zone (SGZ) in the dentate
gyrus (DG) of the hippocampus (Lois & varez-Buylla, 1994). Even though adult
neural stem cells have the capacity to generate new functional neurons, their
regeneration is limited. This is in part due to newly generated neuron stem cells
having to migrate long distances from the site of origin to the site of damage and
subsequent repair. It has been reported that more than 80% of these immature
neurons die before they reach the damaged region during the first week after
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stroke, and only a small fraction of damaged neurons can be replaced (Arvidsson
et al, 2002). Therefore, transplantation of in vitro generated neurons is a potential
avenue for promoting cerebral repair after neuron damage.

Generation of Neurons from Stem Cells In vitro
Stem cells can differentiate into neural lineages that can in turn replace lost
neurons. Preclinical experimental studies have included the application of human
stem cells from various sources including BM stromal cells, embryonic stem cells,
and adipose tissue progenitor cells (Deng et al, 2001; Lenka et al, 2002; Ning et
al, 2006; Sanchez-Ramos et al, 2000; Woodbury et al, 2000). Transplanted
embryonic neurons can survive and ameliorate neurological deficits in
Parkinson’s and stroke models (Hicks et al, 2009; Kim et al, 2002; RodriguezGomez et al, 2007; Takagi et al, 2005), respectively. A recent study indicated
that transplantation of dopaminergic neurons generated from endometrium could
rescue dopamine concentrations in a Parkinson’s animal model (Wolff et al,
2011). Furthermore, in a clinical trial, transplanted embryonic dopamine neurons
have been shown to survive in vivo, leading to promising clinical success (Freed
et al, 2001).

Taken together, recent studies on generating MKs, PLTs and neurons from stem
cells is of increasing interest, because of the promising role of MKs and PLTs in
transfusion medicine and neurons in transplantation therapy. Stem cells sources
include embryonic stem cells (Fujimoto et al, 2003; Gaur et al, 2006; Nishikii et al,
10	
  
	
  

	
  

2008; Takayama et al, 2008) and HSCs from BM, peripheral blood (PB) and cord
blood (CB) (Mattia et al, 2002; Proulx et al, 2003; Shim et al, 2004). However,
there are several strengths and limitations of these sources. Human embryonic
stem cells provide the feasibility of obtaining abundant of MKs, PLTs and
neurons. However, ethical and political issues, potential for tumor formation and
the sophisticated experiment technique inherent in their production are
formidable obstacles. The limited proliferative ability of HSCs also has been
pointed out as a limitation. All of these issues hamper the widespread use of
these sources.
Recently endometrial tissue has been identified as a source of multipotent cells
that are capable of differentiating into smooth muscle cells, adipocytes,
chondrocytes, and osteoblasts (Gargett et al, 2009). hESCs can be relatively
simply isolated and maintained in cell culture. Further, hESCs can be used as an
autologous stem cell source, thereby obviating concerns regarding graft rejection
in humans. Currently, there are no reports on generating MKs and PLTs from
hESCs. And only one recent publication has even described the possibility of
generating neurons from hESCs with combinational inducers (chemical
compound and cytokines) (Wolff et al, 2011). In the present study, we explored
whether hESCs could be differentiated into two distinct cell lines, MKs/PLTs and
neurons, in in vitro culture systems.
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II. HYPOTHESIS AND SPECIFIC AIMS

Hypothesis:
It is hypothesized that human endometrial stromal progenitor cells(hESCs) could
be differentiated into MKs/PLTs or neurons in in vitro culture systems.
Specific Aims:
Aim-1: To set up a method to culture stromal progenitor cells from human
endometrial tissue.
Aim-2: To investigate the feasibility of differentiating hESCs into MKs in an in
vitro culture system and to evaluate the function and morphology of PLTs
released from the generated MKs.
Aim-3: To explore the possibility of neuron differentiation from hESCs in an in
vitro culture system.
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III. EXPERIMENT DESIGN
Aim-1:
Endometrial tissues were collected from selected patients and transferred to the
laboratory. The endometrium layer was then dissected, minced, and
enzymatically digested into a single-cell suspension. The hESCs were cultured
for 4-6 passages and identified by immunocytochemistry and flow cytometry
analyses.
Aim-2:
Passages 4-6th of hESCs were cultured in serum-free medium with TPO (50
ng/ml) (differentiation group) or without (control group) for to investigate their
ability to differentiate into MKs and subsequently generate PLTs. Generated MKs
were identified by flow cytometry and immunocytochemistry methods. Produced
PLTs were collected from culture medium and analyzed by flow cytometry. The
produced PLTs were characterized functionally by thrombin stimulation study
coupled with flow cytometry analysis and electronic microscopic examination.
Aim-3:
hESCs were cultured in medium with (differentiation group) or without (control
group) cytokines (10 ng/ml EGF, 10 ng/ml FGF, 10 ng/ml NGF, 15 ng/ml BDNF)
for investigating their ability for differentiating into neurons. Generated neurons
were determined by immunocytochemistry and western blot analysis of the
expressions of transcriptional genes (Oct4 and Sox2).
13	
  
	
  

	
  

Collection of 1 hr
endometrial
tissue

Isolation
and
culture
hESCs

P4-P6

hESCs identification
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MK/PLT differentiation in medium
containing thrombopoietin (TPO,
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IHC and flow cytometry
(CD90, cytokaretin,
CD29, CD34, CD45)

Neuron differentiation in medium
containing growth factors (EGF,
FGF,BDNF, NGF) for 14 days

IHC and flow cytometry
analysis of MKs (CD41a,
CD42b)

IHC (nestin, β tubulin III,
NeuN, TH, GFAP)

Transmission electron
microscopy study of PLTs

WB analysis of
transcription genes
expression (Oct4, Sox2)

Functional study of PLTs
(thrombin stimulation induced
CD62p expression and
Fibrinogen binding)

Fig 3. The flow chart shows our experiment protocol. IHC: immunocytochemistry;
WB: western blotting.

MATERIALS AND METHODS
Materials
Cytokines
TPO and BDNF were purchased from BD Biosciences (San Jose, CA). FGF,
EGF and NGF were purchased from Lonza (Walkersville, MD).
14	
  
	
  

	
  

Antibodies
PE-conjugated mouse anti-human CD90, PE-conjugated mouse anti-human
CD29, FITC-conjugated mouse anti-human CD45, FITC-conjugated mouse antihuman CD34, PE-conjugated mouse IgG1, FITC-conjugated mouse IgG1, FITCconjugated mouse anti-CD62P, purified mouse anti-human CD41a, and purified
mouse anti-human CD42b were purchased from eBioscience (San Diego, CA).
FITC-conjugated mouse anti-human CD41a, FITC-conjugated mouse anti-human
CD42b, FITC mouse IgG1 isotype control, and mouse anti-CD90 antibody were
purchased from BD Biosciences (San Jose, CA). Mouse anti-Sox2 was
purchased from R&D systems (Minneapolis, MN). Rabbit anti-Oct4 was
purchased from Abcam Inc (Cambridge, MA). Cy3-conjugated donkey antimouse, Cy3-conjugated donkey anti-rabbit, FITC-conjugated goat anti-rabbit,
FITC-conjugated goat anti-mouse, and HRP-conjugated antibodies were
purchased from Jackson lmmunoResearch Lab (West Grove, PA). Mouse anticytokeratin antibody was purchased from Dako (Carpinteria, CA). Nestin, antitubulin, NeuN, and TH were purchased from Millipore (Temecula, CA). GFAP
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor
488-labeled human fibrinogen, Alexa Fluor 488-conjugated mouse IgG isotype
control, and flow cytometry size calibration kit were purchased from Invitrogen
(Carlsbad, CA). β-actin was purchased from Sigma (Fairfax, VA).
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Reagents
DMEM/F12, IMDM, iron saturated transferrin, L-glutamine, dNTP set, FBS,
antibiotic-antimycotic solution, trypsin, and HEPEs were purchased from
Invitrogen (Carlsbad, CA). NPBM was purchased from Lonza (Walkersville, MD).
70 µM wire sieve was purchased from BD Biosciences (San Jose, CA). DNAse1,
Human insulin, BSA, 2-β-mercaptoethanol, nucleotide kit, PI, RNAase, thrombin,
glutaraldehyde,	
  propylene oxide, and spurr resin 812 were purchased from
Sigma (Fairfax, VA). Collagenase was purchased from Roche Applied Science
(Indianapolis, IN). Uranyl acetate and lead citrate were purchased from Fisher
Scientific (Pittsburgh, PA). Osmium tetroxide was purchased from Electron
Microscopy Science (Hatfield, PA).
	
  

Methods
Harvesting Human Endometrium Tissue Sample
Premenopausal women (30-45 years old) who were undergoing hysterectomy for
benign disease indications, leiomyoma, were selected. Informed consent was
obtained by each patient and patient confidentiality was protected according to
HIPPA guidelines. Ethics approval was obtained from the Institutional Review
Boards and Research Committees at the Miami Valley Hospital and Wright State
University Research Committee for this study.
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Endometrium tissues were obtained for isolation and culture of hESCs. In brief,
after the uterus was removed from the patient, a small tissue sample with full
thickness endometrium attached to myometrium was dissected and collected
immediately. The tissue sample was placed into 20 ml pre-chilled phosphate
buffer saline (PBS) buffer containing 10% FBS and 2% antibiotic-antimycotic
solution (final concentration: 200 µg/ml penicillin G sodium and 200 µg/ml
streptomycin sulfate) and was processed within 30 - 60 min.
Isolation and Culture of hESCs
The endometrium tissue was mechanically and enzymatically digested into a
single-cell suspension as previously reported with slight modifications (Chan et al,
2004;Dimitrov et al, 2008). Briefly, the tissue sample was washed twice with
washing buffer (PBS with 25 µM HEPEs and 1% antibiotic-antimycotic solution)
to remove excess blood. Then the endometrium layer was dissected from the
underlying myometrium, minced into 1-2 mm³ pieces with a sharp surgical
scissor, digested in enzyme digestion buffer (PBS with 25 µM HEPEs, 1mg/ml
collagenase, 0.1mg/ml DNAse1 and 1% antibiotic-antimycotic solution) in a
humidified 5% CO2 / 95% air atmosphere at 37°C for 45 min with a brief shaking
once every 5 min. Then cell suspension was filtered through a 70 µm wire sieve
to remove mucus and undigested tissue. The filtrates were centrifuged at 400 × g
for 10 min to collect cells. 0.9 ml ammonium chloride solution was added to lyse
excess erythrocytes for 10 min on ice, followed by centrifugation at 400 × g for 10
min, the cell pellets were resuspended with hESCs culture medium (DMEM/F12
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supplemented with 10% FBS and 1% antibiotic-antimycotic solution). Cells were
plated in 6-well tissue culture plates, allowed to adhere overnight in a humidified
5% CO2/95% air atmosphere at 37°C and cultured as monolayer cells.
For passaging, when cells reach 90% confluence, they were treated with 1.5
ml/well 0.025% trypsin/0.01% EDTA at 37°C for 7 min, then an equal volume of
complete DMEM/F12 with 10% FBS medium was added to deactivate the
enzyme reaction. Cells were then pelleted. Supernatant was discarded. Pelleted
cells were resuspended with hESCs culture medium, split in a 1:3 ratio and
cultured until the 4th passage. The culture medium was replaced with fresh warm
medium every 2-3 days.

Identification Study of hESCs
Cultured cells at the 4th passage were analyzed by indirect immunocytochemistry
and flow cytometry as previous described (Dimitrov et al, 2008;Gargett et al,
2009).
In brief, for immunocytochemistry staining, a proportion of cells were seeded on
coverslips and incubated overnight. After 2 washes with PBS, the cells were fixed
with 2% paraformaldehyde (PFA) for 20 min, treated with blocking buffer (PBS
with 3% BSA and 3% normal donkey serum) for 1hr at room temperature (RT).
Subsequently the cells were incubated with primary monoclonal antibodies
mouse anti-human CD90 (Thy-1) (1:25) or mouse anti-human cytokeratin (1:50)
overnight at 4ºC. Following by 3 washes with PBS/0.1% BSA, the cells were
incubated with secondary antibody, Cy3-conjugated donkey anti-mouse IgG
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(1:250), for 1 hr at RT. Washed with PBS/0.1% BSA 3 times (3 min each),
mounted with fluorescence mounting medium and imaged under a fluorescence
microscope (Leica, Germany).
For flow cytometry analysis, cells were trypsinized at 90% confluence as above
described, centrifuged at 400 × g for 10 min. Cell pellets were resuspended and
incubated with either PE-conjugated anti-human CD29 and FITC-conjugated
anti-human CD45, or PE-conjugated anti-human CD90 and FITC-conjugated
anti-human CD34 for 30 min at 4ºC in the dark, individually. Isotype matched
(IgG) non-specific antibodies served as negative controls. Final volume per tube
was brought to 100 µl for flow cytometric analysis using Accuri C6 flow cytometer
and CFlow Plus Analysis software (Ann Arbor, MI). Cells were selected for
analysis on the basis of their forward versus side scatter profile to exclude dead
cells and debris. All antibody application concentrations followed manufacture
instructions and guidelines.

Differentiation of MKs and PLTs from hESCs
In order to differentiate hESCs into the MK lineage, the 4th passage of hESCs
were trypsinized with 0.025% trypsin/0.01% EDTA, centrifuged at 400 × g for 10
min, counted using a hemacytometer, and seeded as1.8 x 105 cells/well on 6-well
tissue culture plates or coverslipes with hESCs culture medium overnight. Then
culture medium was removed and replaced with fresh induction IMDM medium
supplemented with 50 ng/ml TPO, 0.5% BSA, 200 µg/ml iron saturated
transferring, 10 µg/ml insulin, 2 mM L-glutamine, 4 µg/ml LDL cholesterol, 50 µM
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2-â-mercaptoethanol, 20 µM each nucleotide, 20 µM dNTP and 1% antibioticantimycotic solution. Cells were cultured for 18 days. One half of the culture
medium was replaced in the first 10 days, then all of the culture medium was
changed from day 10-18 to collect PLTs from the medium supernatant. Control
cells were cultured in complete culture medium (IMDM with 10% FBS and 1%
antibiotic-antimycotic solution) without TPO for 18 days. Cells on coverslips were
used for MK immunocytochemistry studies.

Characterization Study of MKs Differentiated from hESCs
MKs generated from hESCs were determined by immunocytochemistry and flow
cytometry analyses.
For immunocytochemistry, cells on coverslips were fixed with 2% PFA for 20 min
at RT, washed with PBS/0.1% BSA 3 times, permeabilized with goat serum
blocking buffer (PBS/0.1% BSA and 0.3% triton-100) for 30 min at RT, then
incubated with prediluted purified mouse anti-human CD41a (glycoprotein αIIb)
and purified mouse anti-human CD42b (glycoprotein αIb) primary antibodies
overnight at 4°C. The cells were washed 3 times (5 min each), then incubated
with secondary antibody FITC-conjugated goat anti-mouse (1:100), individually,
followed by another 3 washes, the cells were incubated with PI/PBS solution in
the presence of RNAse (PI/RNAse final concentration: 20 µg/ml) for 15 min at RT
in the dark, then mounted with fluorescence mounting solution and imaged under
a confocal fluorescence microscope (Leica TCS SP2, Leica, Germany). To
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assess the differentiation rate, we counted the number of cells staining positive
with a given antibody in 5 individual fields. Control cells were stained
concurrently.
For flow cytometry, the cells were detached with 0.025% trypsin/0.01% EDTA,
centrifuged at 800 × g for 10 min to pellet the MKs. MKs were then resuspended
and fixed with 2% PFA for 20 min at RT, washed with PBS/0.1% BSA 3 times,
centrifuged at 800 × g for 10 min, permeabilized with blocking buffer (PBS/0.1%
BSA and 0.3% triton X-100) for 30 min at RT. This was followed by incubation
with fluorescence conjugated antibodies, FITC-conjugated anti-CD41a, FITCconjugated anti-CD42b and FITC-conjugated mouse IgG1 isotype control, for 30
min at 4°C in the dark, respectively. The cells were then washed with PBS/0.1%
BSA, centrifuged and incubated with 100 µl PBS/0.1% BSA buffer with PI
solution (20 ug/ml) containing RNAase (20 ug/ml) for 30 min at RT in the dark.
Samples were analyzed by an Accuri C6 flow cytometer and CFlow Plus Analysis
software. CD41a+cells were defined as MKs and were gated for MK ploidy
analysis. All antibody application concentrations followed manufacture
instructions and guidelines. Control cells were analyzed simultaneously.

Characterization Study of PLTs Generated from hESCs
PLTs released from generated MKs were defined by flow cytometry analysis.
Briefly, culture medium was gently collected from day 10-18 with a 15 ml
centrifuge tube and centrifuged at 150 × g for 20 min to eliminate any large cells.
The supernatant was fixed with 2% PFA for 20 min at RT, centrifuged at 1700 × g
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for 30 min to sediment a PLT pellet. When storing PLTs, the pellet was
resuspended with PBS/1% FBS, and stored at 4°C for further analysis. Then
fixed and stored PLT pellet were combined, resuspended and incubated with
FITC-conjugated anti-CD41a antibody and FITC-conjugated mouse IgG1 isotype
control for 30 min at 4°C in the dark, individually. The total volume per tube was
brought to 100 µl with PBS/0.1% BSA. 2 µm and 4 µm flow cytometry calibration
bead solution was added into each tube. All samples were analyzed using the
Accuri C6 flow cytometer. The application concentrations of calibration beads
and antibodies followed manufacture instructions and guidelines.

Functional Study of Generated PLTs with Thrombin Stimulation
The functional capabilities of generated PLTs were analyzed for both fibrinogen
binding and surface antigen CD62P expression in the presence or absence of
agonist thrombin.
To prepare cell samples, PLTs were collected as described above. The PLT
pellets were resuspended in a modified Tyrode-HEPEs buffer (138 mM NaCl,
0.36 mM NaH2PO4, 2.9 mM KCl, 12 mM NaHCO3, 10 mM HEPEs, 5 mM glucose,
1 mM MgCl2, and 1 mM CaCl2, pH 7.4).
The ability of fibrinogen to bind surface receptors on activated PLTs is a
prerequisite for PLT aggregation. To determine fibrinogen binding, PLTs were
stimulated by thrombin (5U/ml) for 10 min at 37°C without stirring in the presence
of Alexa Fluor 488-labeled human fibrinogen (100 µg/ml) or isotype control
mouse IgG, respectively. A control group of PLTs underwent concurrent testing.
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The control PLTs were stained with Alexa Fluor 488-labeled fibrinogen or isotype
control antibodies without thrombin stimulation. All sample mixtures were then
diluted with HEPEs buffer. The final volume each sample was brought to 100 µl.
All samples were analyzed by Accuri C6 flow cytometer.
The agonist thrombin is responsible for PLT activation and is measured as
CD62P expression. To determine the surface expression of P-selectin (CD62P),
PLTs were stimulated with 5 U/ml thrombin for 10 min at 37°C, then fixed with
2% PFA for 30 min at RT, washed twice with HEPEs buffer, incubated with either
FITC-conjugated anti-CD62P or FITC-conjugated mouse IgG isotype control for
30 min at 4°C in the dark. A control group of PLTs underwent concurrent testing.
The control PLTs were fixed without thrombin stimulation and stained. The final
volume each sample was brought to 100 µl. All samples were analyzed by Accuri
C6 flow cytometer. All antibody application concentrations followed manufacture
instructions and guidelines.

Morphologic Study of PLTs by TEM
Culture medium containing PLTs released from generated MKs was gently
collected and centrifuged at 150 × g for 20 min to remove nucleated cells. .
Control samples of PLTs were obtained from human peripheral blood samples.
Peripheral blood was collected from normal patient using standard phlebotomy
techniques into a collection tube containing acid-citrated-dextrose (ACD) solution.
The control blood sample was centrifuged at 150 × g for 20 min in order to obtain
platelet-rich plasma (PRP). The supernatant and PRP were added with equal
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volume of 0.5% glutaraldehyde in 0.1 M phosphate buffer, then centrifuged at
1000 × g for 10 min to pellet PLTs. The pellets were then fixed with 500 µl 2%
glutaraldehyde in 0.1 M phosphate buffer for 1 hr at 4°C and centrifuged again at
1000 × g for 10 min. The samples were washed with 0.1 M phosphate buffer 3
times (1 min each), fixed with 1% osmium tetroxide in 0.1 M phosphate buffer for
2 hrs at 4°C and washed another 3 times (1 min each), then dehydrated with a
graded ethanol series (50%, 75%, 95%, 100%) for 5 min each. Subsequently, the
samples were treated with 100% propylene oxide 2 times (5 min each), and then
treated with 1:2 ratio of spurr resin 812 and propylene oxide, followed by a 2:1
ratio of spurr resin 812 and propylene oxide for 2 hrs. Finally, the samples were
embedded in beam capsules with spurr resin 812 according to the manufacture’s
instruction, baked at 60°C in a hot air oven overnight. Ultrathin sections (60-80
nm) were prepared with MT7000, mounted on 300-mesh copper grids, stained
with 2% uranyl acetate for 5 min, rinsed with double distilled water for 5 times,
and allowed to dry. The specimens were then stained with lead citrate for 10 min
(REYNOLDS, 1963), rinsed with double distilled water another 5 times and
allowed to air dry. Finally, all specimens were examined with an EM 208 (Philips)
transmission electron microscope at an accelerating voltage of 70 KV.

Differentiation of Neurons from hESCs
To differentiate hESCs into the neuron lineage, the 4th passage of hESCs were
trypsinized as noted in the previous sections and cultured at a density of 1.6 ×
105 cells/well on fibronectin coated 6-well tissue culture plates or coverslips with
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hESCs culture medium overnight. The culture medium was then removed and
replaced with fresh NPBM medium supplemented with growth factors including
10 ng/ml FGF, 10 ng/ml EGF, 10 ng/ml NGF,15 ng/ml BDNF, and 0.2 mM Lglutamine and 1% antibiotic-antimycotic solution. Cells were cultured for 14 days.
Control cells were cultured simultaneously in control culture medium (DMEM/F12
with 10%FBS and 1% antibiotic-antimycotic solution) without cytokines for the
same time period as the study cells.

Immunofluorescence Staining of Generated Neurons
The cells on coverslips were fixed with 2% PFA, washed with PBS,
permeabilized with blocking buffer (goat serum or donkey serum with PBS/0.1%
BSA and 0.3% triton X-100) for 30 min at RT, then incubated with rabbit antinestin (1:200), mouse anti-β tubulin III (1:50), mouse anti-NeuN (1:50), rabbit
anti-TH (1:1000), rabbit anti-GFAP (1:25) monoclonal antibodies overnight at 4°C
in the dark, respectively. After 3 times washes, cells were incubated with
corresponding secondary antibody Cy3-conjugated donkey anti-rabbit/mouse
(1:250) or FITC-conjugated goat anti-mouse/rabbit (1:100) for 1 hr at RT,
individually. Subsequently, cells were washed 3 times, incubated with 1 ml DAPI
solution (final concentration: 0.4 µg/ml) for 5 min, mounted with fluorescence
mounting solution and imaged under a confocal fluorescence microscope. To
assess the differentiation rate, we counted the number of cells staining positive
with a given antibody in 5 individual fields. Controls were imaged simultaneously.
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Western Blot Analysis of Transcription Gene Expression in Differentiated
Neuronal Cells
Protein samples were obtained from undifferentiated hESCs and
differentiated neuronal cells following treatment with lysis buffer. Briefly, culture
medium was removed from both groups. Cells were washed with PBS 3 times (1
min each). The cells were then scraped off the culture plates in 1 ml PBS,
transferred to1.5 ml tubes, and centrifuged at 400 × g for 10 min. 50 µl ice-cold
lysis buffer containing protease inhibitor was added to each cell pellet. Samples
were centrifuged at 10,000 × g for 5 min. The supernatants were collected as
protein. Protein concentrations were determined by the Bradford method using
Bio Rad reagent (Bio Rad Laboratories, Hercules, CA). For gel loading, the final
sample volume was corrected to 30 µg of total protein. To each of the samples,
10 µl of loading buffer (40% glycerol, 50% Tris-HCL, 10% SDS, bromophenol
blue, 0.4% β-mercaptoethanol) was added to samples and boiled for 5 min. Then
samples were loaded onto 10% Tris-Glycine SDS-Page gel (Bio Rad
Laboratories, Hercules, CA). The gel was electrophoresed at 100 V, 50 mA till
the dye came close to the bottom of the gel. Proteins were transferred from the
gel to a PVDF membrane overnight at 10 V, 50 mA. Then the PVDF membrane
was blocked with 8 ml 5% non-fat milk in 1 × TBS-T buffer for 1 hr at RT. The
primary monoclonal antibody rabbit anti-Oct4 (1:500) was probed and incubated
overnight at 4°C. The membrane was washed with1× TBS-T buffer for 3 times (5
min each), then probed with secondary antibody horse raddish peroxidase (HRP)
conjugated goat anti rabbit (1:4000) for 1 hr at RT, washed with 1× TBS-T for 3
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times more, and viewed via the chemiluminescence produced by the ECL
substrate (Pierce) and captured by the Fuji LAS3000 imager (Japan).
Subsequently, the membrane was washed with 1× TBS-T buffer another 3 times
(5 min each), then stripped with stripping buffer for 15 min at RT, blocked with
non-fat milk, incubated with primary monoclonal antibody mouse anti-Sox2
(1:2000) overnight at 4°C, probed with secondary antibody HRP-conjugated
donkey anti mouse (1:4000), washed and imaged as described above. β-actin
was used to determine relative amounts of protein of interest (POI) as follows:
normalized value: (POIdensity - Backgrounddensity) / ( Actindensity - Backgrounddensity).
To do this, monoclonal antibody mouse anti β-actin (1:4000) and secondary
antibody HRP-conjugated donkey anti mouse (1:40000) were used. Values were
not excluded from the final data calculations unless one of the bands was
missing. This method of simultaneous probing is well-established and has been
described previously (Mouihate et al, 2002).

Statistic Analysis
Results were described as mean ± SEM from at least three independently
conducted experiments, unless otherwise specified. The p value < 0.05 was
considered to be statistically significant in the paired t-test. All experiments were
repeated in triplicate and were all reproducible.
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IV. RESULTS

1. Morphology of hESCs
Three days after plating, the cultured cells grew and formed small colonies (Fig
4A). Then small colonies gradually formed large colonies (Fig 4B) and eventually
formed a monolayer at approximately days 8-10 of culture (Fig 4C).
A

B

C

	
  	
  

Fig 4. Morphological study of hESCs under light microscope. Representative
images of cultured cells: small colonies (A), large colonies (B), and confluence
hESCs (C). All magnification: 10 ×.

2. Characterization of hESCs
After the 4th passage culture, the hESCs were identified by immunocytochemistry
and flow cytometry. Using flow cytometry, the cultured cells highly positively
stained with stromal cell specific markers CD90 (Fig 5A) and CD29 (Fig 5B),
however, negatively stained with hematopoietic lineage markers CD45 (Fig 5C)
and CD34 (Fig 5D). Summarized data (Fig 5E) demonstrated the percentages of
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phenotypic expression of CD90 (95.2 ± 2%, n=3), CD29 (96.4 ± 3%, n=3), CD45
(1.2 ± 0.05%, n=3), and CD34 (1.15 ± 0.08%, n=3).
Immunocytochemistry revealed the cultured cells exclusively positively stained
CD90 (stromal marker) (Fig 5F), but negatively stained cytokeratin (epithelial
marker) (Fig 5G).

Fig 5. hESCs identification. Flow cytometric representative plots: A, CD90

expression; B, CD29 expression; C, CD45 expression; D, CD34 expression
(Black curve: antibodies; Red curve: isotype control); E, summarized data.
Data was analyzed as mean ± SEM, n=3, respectively. Immunocytochemistry

data: F, CD90 staining; G, cytokeratin staining (Magnification: 20 x).
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3. Characterization of hESCs-derived MKs by Immunocytochemistry
Analysis
After 7-10 days of differentiation, generated MKs could be visualized under the
light microscope (Fig 6A). Upon immunofluorescence staining, the generated
MKs positively expressed CD41a (Fig 6B1- 6B3) and CD42b (Fig 6C1- 6C3).
Summarized data (Fig 6D) demonstrated the percentages of phenotypic
expression of CD41a (38 ± 3% and 1 ± 0.5%, differentiation group vs. control
group, P<0.01, n=3), and CD42b (27 ± 2.5% and 0.9 ± 0.4%, differentiation
group vs. control group, P<0.01, n=3) in generated MKs.
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Fig 6. Characterization of hESCs - derived MKs by immunocytochemistry. A,
generated MKs can be observed under light microscope after 7-10 days
differentiation. B1, CD41a staining, C1,CD42b staining; B2-C2, PI staining; B3C3, merged; scale bar: 75 µm. D, summarized data shows MKs marker
expression on differentiation and control cells. Data was analyzed as mean ±
SEM, *P < 0.01, n=3.
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4. Expression of Surface Protein Markers for hESCs-derived MKs by Flow
Cytometric Analysis
The flow cytometric data showed the positive expression of CD41a (Fig 7A), and
CD42b (Fig 7B). Summarized data (Fig 7C) demonstrated the positive
expression percentages of CD41a (39 ± 3% and 1 ± 0.09%, differentiation group
vs. control group, P<0.01, n=3), and CD42b (28 ± 2% and 1.2 ± 0.06%,
differentiation group vs. control group, P<0.01, n=3). This MK percentage values
closely paralleled to those obtained from immunocytochemistry analysis. They
were also consistent with the developmental scheme, because CD41a is
expressed throughout megakaryocytopoiesis, while CD42b is expressed during
the later stages of MK lineage developmental (Tomer, 2004). The number of MKs
produced was approximately 5.5 x 104 MKs (CD41a +) versus 1.8 x 105 hESCs.
Undifferentiated hESCs (control) were diploidy and the DNA ploidy was 2N (Fig
7D). Generated MKs were polyploidy and the DNA ploidy ranged from 2N to16N
(Fig 7E).
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Fig 7. hESCs-derived MKs surface protein expression analysis by flow
cytometry. Representative plot of CD41a expression (A), and CD42b expression
(B) (Black curve: antibodies; Red curve: isotype control); Summarized data (C)
shows MK markers expression on differentiation and control cells. Data was
analyzed as mean ± SEM, *P<0.01, n=3. Plot D shows DNA content of
undifferentiated hESCs; Plot E shows the polyploidy of generated MKs.
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5. Expression of Surface Protein Markers for PLTs by Flow Cytometric
Analysis
Culture-derived PLTs were collected from the culture supernatant and incubated
with fluorescence-conjugated antibody CD41a as described in the Materials and
Methods section. The diameter of the PLTs is approximately 2-3 µm. A gate was
fixed in the forward scatter and side scatter histogram by using of 2 µm and 4 µm
calibration beads (Fig 8A). Collected PLTs were expressed with CD41a (90 ± 2%,
n=3) within the fixed gate P1 (Fig 8B). The number of PLTs produced was
approximately 3 x 105 PLTs versus 1.8 x 105 hESCs. PLT numbers were reported
as a cumulative number up to the point of analysis. Summarized data (Fig 8C)
showed the MK yield per input of hESC was approximately 0.31 ± 0.01(n=3), the
MK yield per input of hESC was approximately 1.7 ± 0.25 (n=3). 	
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Fig 8. Generated PLTs surface protein expression analysis by flow cytometry. A,
representative plot shows the population of PLTs (oval); 2 µm (circle) and 4 µm
(square) calibration beads were used as internal size standards; B, CD41a
expression in the cells gated on P1 (black curve, red curve: isotype control). C,
summarized data of MK and PLT yield per input of hESC. Data was expressed
as mean ± SEM, n=3.

6. Expression of Activation-dependent Antigens on Generated PLTs
Normal functional PLTs, express certain cell surface antigens like CD62P and
fibrinogen receptor (αIIbIIIa) when activated. P-selectin, presents on the surface
of the α-granules of resting PLTs, and is mobilized to the plasma membrane after
activation. The PLTs surface protein complex fibrinogen receptor αIIbIIIa changes
confirmation after PLTs activation in its conversion to a functional fibrinogen
receptor.
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Our flow cytometric data showed that the generated PLTs expressed CD62P
(Fig 9A) and exhibited fibrinogen binding capability (Fig 9C). Summarized data
(Fig 9B) demonstrated the up-regulation of CD62P expression (26 ± 4 % and 2.5
± 1%, thrombin stimulation group vs. control group, P<0.01, n=3) after thrombin
stimulation. Summarized data (Fig 9D) showed the raise of fibrinogen binding
(32 ± 3 % and 1 ± 0.4 %, thrombin stimulation group vs. control group, P<0.01,
n=3) after thrombin stimulation. These results indicated that generated PLTs
have the ability to become active PLTs.
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Fig 9. Functional assay of the generated PLTs. Thrombin stimulation enhanced
CD62P expression (A) and fibrinogen binding (C) in PLTs released from
generated MKs (Black curve, thrombin stimulation; Red curve, isotype control).
Summarized data show the significant up-regulation of CD62P expression (B)
and fibrinogen binding (D) after thrombin activation. Data was analyzed as
mean ± SEM, *P<0.01, n=3.
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7. Ultrastructural Similarities between Generated PLTs and Peripheral
Blood Derived PLTs
Generated PLTs were examined by TEM. The size and ultrastructural
composition of the generated PLTs (Fig 10A and C) were similar to those of
normal PLTs obtained from human peripheral blood (Fig 10B and D). A
representative image of generated PLT displayed a discoid shape shown in Fig
10C, similar in shape to the peripheral blood PLTs shown in Fig 10D. Generated
PLTs also showed typical normal PLT features, such as storage granules and
mitochondria.
A
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Fig 10. Electron micrographs of PLTs. Generated PLTs (A, C) show typical
ultrastructural morphology and cellular organelles as PLTs obtained from
peripheral blood (B,D). G: storage granules; M: mitochondria.
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8. Expression of Surface Protein Markers for hESCs-derived Neurons by
Immunocytochemistry Analysis
After 14 days differentiation, generated neurons exhibited typical neuronal
morphology including pyramidal cell bodies and dendritic projections (Fig 11A)
upon light microscopic examination. Immunocytochemical staining revealed that
generated neurons were positively stained for neuron specific markers including
nestin (Fig 11B1-B3), β-tublin III (Fig 11C1-C3), NeuN (Fig 11D1-D3), TH (Fig
11E1-E3), and astrocyte marker GFAP (Fig 11F1-F3). Summarized data (Fig
11G) showed the percentages of phenotypic expression of nestin (40 ± 4%, n=3),
β-tublin III (37 ± 3%, n=3), NeuN (15 ± 2%, n=3), TH (14 ± 1%, n=3), and
astrocyte marker GFAP (10 ± 3%, n=3). The control cells weakly expressed
neuron and astrocyte markers (less than 1%).
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Fig 11. Characterization of generated neurons. A, hESCs treated with neuron

differentiation medium for 14 days (Magnification 20 x); B1, nestin staining; C1,
β-tublin III staining; D1, NeuN staining; E1, TH staining; F1, GFAP staining; B2F2, DAPI staining; B3-F3, merged; scale bar, 75 µM. G, summarized data. Data

was analyzed as mean ± SEM, n=3.

9. Expression of Transcription Genes Oct4 and Sox2 in the Cells after
Neuronal Differentiation
Western blotting data showed the expressions of Oct4 (Fig 12A) and Sox2 (Fig
12B) on undifferentiated hESCs (control) and differentiated neuronal cells.
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Summarized data (Fig 12C) demonstrated the significantly down-regulated
expression of transcription genes (Oct4: 0.11 ± 0.01and 0.32 ± 0.01, and Sox2:
0.25 ± 0.02 and 0.52 ± 0.03, differentiated group vs. control group, P<0.01, n=4)
in generated neurons.
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Fig 12. Comparison of the transcription genes expression in neuron
differentiation and control cells. Representative bands show the decreased
expression of Oct4 (A) and Sox2 (B) in neuronal differentiation cells as
compared with control cells. Summarized data (C). Data was analyzed as mean

± SEM, *p<0.01, n=4.
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V. DISCUSSION

The major findings of this study are as follows. 1) MKs and functional PLTs can
be generated in vitro from hESCs. The generated PLTs have similar
ultrastructural morphology and functional features with normal PLTs from human
peripheral blood. 2) Neuons can also be differentiated from hESCs in an in vitro
culture system.
Human endometrium is characterized by its self-renewal and cyclic regeneration
as part of the normal physiologic course of menstrual cycle in reproductive age
females. The upper functionalis layer is shed at menstruation and is thought to
regenerate, to a thickness of 0.5 - 1 mm to 5 - 7 mm, from progenitor cells
located in the remaining basalis layer (Padykula, 1991). Recent studies have
provided evidence for the existence of stromal progenitor cells in endometrium
(Chan et al, 2004;Dimitrov et al, 2008;Schwab et al, 2005;Wolff et al, 2011).
Based on these reports, we cultured hESCs from human endometrial tissue in
this study. The primary cultured cells were composed of a heterogeneous
population of stromal cells, epithelial cells and erythrocytes. As Dimitrov et al
reported that the frequency of the cells other than hESCs diminishes quickly
through 2 - 3 passages in the culture system (Dimitrov et al, 2008), we used
passages 4 - 6th of hESCs for the differentiation in our experiments. We found
that the cultured hESCs of passages 4-6th exclusively expressed stromal cell
marker CD90 with none cells expressing epithelial cell marker cytokeratin by
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immunocytochemistry analysis. Further analysis by flow cytometry convincingly
demonstrated that more than 95% hESCs (P4-P6) were positive for stromal cell
markers (CD29 and CD90) and negative for hematopoietic cell markers (CD34
and CD45). These data are in agreement with previous findings that showed
similar phenotypic expression profiles for their respective hESCs (Chan et al,
2004; Dimitrov et al, 2008; Schwab et al, 2005), demonstrating the stromal
progenitor cells exist in the endometrial tissue.
Recent studies have reported on hESCs as a source of multipotent cells that are
capable of differentiating into multiple cell lineages including smooth muscle cells,
adipocytes, chondrocytes, and osteoblasts (Gargett et al, 2009). Additionally, one
recent publication described neuron differentiation potentiality from hESCs (Wolff
et al, 2011). But there are no reports on generating MKs and PLTs from hESCs.
The process of MK differentiation and subsequent PLT release by mature MKs
are influenced by a variety of cytokines and growth factors. TPO is the primary
cytokine to support the proliferation and maturation of MKs (Alexander et al, 1996;
Gurney et al, 1994; Kaushansky et al, 1994; Kaushansky, 1995; Schipper et al,
1998). It also plays an important role in the formation and function of PLTs in
vitro (Choi et al, 1995; Choi et al, 1996; Kaushansky, 1998). Hence, TPO has
been widely used in research and in a number of studies on MK and PLT
differentiation (Chen et al, 2009; Fujimoto et al, 2003). Serum is an important
supportive component in cell cultures, but it is also a potential source of bacterial,
mycoplasmal, and viral contamination and could induce immune-response.
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Herein, we firstly described a culture system in which MKs and PLTs can be
differentiated from hESCs in serum-free medium supplemented with TPO. The
hESCs-derived MKs and PLTs expressed typical MK and PLT specific plasma
membrane glycoprotein markers (eg, CD41a, CD42b). Stimulation of generated
PLTs through soluble agonist thrombin resulted in activation of the fibrinogen
receptor (αIIbIIIa) and enhanced expression of surface antigen P-selectin
(CD62P). Electron microscopy studies showed that our generated PLTs have
similar morphological and ultrastructural features as PLTs obtained from human
peripheral blood including a discoid shape, the presence of storage granules and
other organelles like mitochondria. These data are consistent with previous
studies about in vitro generated MKs and PLTs from other tissue of origin
sources (Choi et al, 1995;Fujimoto et al, 2003;Matsubara et al, 2009;Ungerer et
al, 2004).
Matsubara and colleagues have generated approximately 2 × 106 MKs and 1.5 ×
105 PLTs from 107 adipocyte precursor cells (Matsubara et al, 2009). The
Takayama group reported that about 2 - 5 ×105 MKs and 105 PLTs were
produced from 105 human embryonic stem cells (Takayama et al, 2008). In the
present study, we obtained approximately 5.5 x 104 MKs and 3 x 105 PLTs from
1.8 x 105 hESCs. The differentiation efficiency of MKs to PLTs among various
stem cell sources renders precise comparisons difficult. However, the number of
PLTs released from our hESCs-derived MKs was below the theoretical range
proposed in other study in which approximately 1000 to 5000 PLTs per MK has
been reported to be released in vivo from mature MKs (Patel et al, 2005).
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Release of PLTs from mature MKs is influenced by multiple factors within the BM
microenvironment (Larson & Watson, 2006;Patel et al, 2005). The low efficiency
of PLT release from hESCs-derived MKs may be related to the absence of some
in vivo stimulus of thrombopoiesis, such as shear flow (Junt et al, 2007), in the in
vitro culture system. Despite these findings, the present study is the first to report
that MKs can be feasibly generated from hESCs and the generated MKs
released PLTs conformed morphologically and functionally with PLTs obtained
from human peripheral blood samples. The capacity to generate functional PLTs
from hESCs in vitro provides a promising source for PLT in transfusion medicine.
Menorrhagia is well recognized as a bleeding disorder in women with inherited
bleeding disorders (James, 2005;Kadir et al, 1999). PFDs are inherited bleeding
disorders frequently found among patients with bleeding diatheses. PFDs occur
in 50% of women with unexplained menorrhagia and are prevalent in adolescent
with menorrhagia as well (Chi et al, 2010; El-Hemaidi et al, 2007; Hossain et al,
2010; Philipp et al, 2003). However, the management of menorrhagia is
suboptimal in some patients with PFDs. Some patients are refractory to medical
therapy and require repeated PLT transfusions. One possible consequence of
this study is in vitro generating PLTs with normal function from hESCs provides a
potential therapeutic approach to menorrhagia.

In the present study we also reported that neurons can be generated from
hESCs in a neuron differentiation medium with growth factors EGF, FGF, NGF
and BDNF. Neurotrophic factors (EGF, FGF, NGF, and BDNF) are survival
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and/or differentiation factors for neuron progenitor cells. EGF plays an important
role in the regulation of cell growth, proliferation and differentiation (Carpenter &
Cohen, 1990). FGF has long been known as a key regulator of neuron stem cell
proliferation and differentiation (Palmer et al, 1999). The importance of FGF in
vivo for neurogenesis has been confirmed by the neural defects observed in
FGF-deficient mice (Vaccarino et al, 1999). NGF is the first of a series of
neurotrophins shown to mediate the survival of neurons (Freeman et al, 2004).
BDNF is found to support the survival of existing neurons, and encourage the
growth and differentiation of new neurons and synapses (Huang & Reichardt,
2001).
In this study, hESCs following neural differentiation revealed
immunocytochemical characteristics of neural lineages. Generated neurons
exhibited neuron morphology including pyramidal cell bodies and dendritic
projections, and positively stained with neuron specific markers nestin (a
filamentous protein expressed by neuronal precursor stem cells) (Lendahl et al,
1990), β tubulin III (a marker expressed in immature neurons) (Lee et al, 1990),
NeuN (a neuron-specific marker expressed in postmitotic cells) (Sarnat et al,
1998), and astrocyte marker GFAP (an intermediate filament protein expressed
by astrocytes in the central nervous system). These results are consistent with
published data of BM stromal cells, which express both neuron and glial cell
markers after neuron induction (Lu et al, 2006;Sanchez-Ramos et al, 2000).
Interestingly, the catecholaminergic marker TH, which is the rate-limiting enzyme
for dopamine synthesis, is also expressed.
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Oct4, a member of the POU family of transcription factors, is characteristically
expressed in embryonic cells and necessary for their pluripotency (Pesce &
Scholer, 2000). Sox2 is one of the SoxB1family of transcription factors, which are
also crucial for stem cell pluripoteny. In our study, we observed that Oct4 and
Sox2 were expressed in the initial hESCs population, suggesting that these
hESCs contain pluripotent progenitors. After neuronal differentiation, the
expression levels of Oct4 and Sox2 were found to be significantly reduced. This
finding is in agreement with previous study that reported Oct4 is expressed by
some individual stromal cells in human endometrium (Matthai et al, 2006) and
supports the neuronal differentiation scheme.
Stroke remains a leading cause of death and disability worldwide. Neural tissue
has limited potential for intrinsic repair following injury. Stem cell therapy is
promising for neural regeneration and thus becomes one of the current trends.
An increasing number of studies have shown that stem cell treatment of stroke
acts to increase cell survival and angiogenesis, improve synapse formation, and
reduce inflammatory responses (Bacigaluppi et al, 2009; Lindvall & Kokaia, 2004;
Martino & Pluchino, 2006). The capacity to generate neurons from hESCs in vitro
provides a promising source of transplantation therapy for stroke and
neurodegenerative diseases.
One shortcoming of the present study was that we relied only on the
morphological changes and protein level of transcriptional genes expression to
define the events during neuroectodermal conversion of hESCs. A previous
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study attempted to perform electrophysiological experiments on putative neurons
derived from hESCs without showing the action potential (Wolff et al, 2011). In
future studies, we will investigate the membrane action current of generated
neurons using standard whole-cell patch-clamp technique and perform the in vivo
transplantation study.
We will also investigate the differentiation efficiency of PLTs generated from
induced pluripotent stem (iPS) cells. iPSCs are a type of pluripotent stem cells
that have been reprogrammed from fibroblast cells obtained from either fibroblast
cells obtained from either human adult dermal cells, fetuses, or newborn foreskin
with defined transcriptional factors (Oct4, Sox2, Klf, C-myc) (Takahashi et al,
2007;Yu et al, 2007). PLTs are terminally differentiated, anucleate cells. PLTs
are unable to retain the pluripotent or tumorigenic properties of iPSCs. A
previous finding has already indicated that MKs and PLTs can be generated from
hiPSCs, and produced PLTs showed normal function in vivo (Takayama et al,
2010). Based on these studies, a feasible approach to overcome the relative low
efficiency issue is to reprogram iPSCs from hESCs and then differentiate the
iPSCs into MKs and PLTs. Such an approach to generating PLTs from hESCs
could potentially lead to a constant and safe source of PLTs.
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VI. CONCLUSION

In conclusion, 1) our results reported on the feasibility of differentiating hESCs
into MKs that subsequently release functional PLTs. This process is achieved
using serum-free medium in the presence of TPO in an in vitro culture system.
The generated PLTs have the potential to serve as an alternative source of PLT
concentrates for future use in transfusion medicine to treat PLT-related bleeding
disorders like menorrhagia.
2) Our data demonstrated that hESCs can be differentiated into neurons
accompany with reduced expression of multipotent transcription genes (Oct4 and
Sox2). Correspondingly, these data indicate that hESCs could serve as an
alternative source for producing neurons in an in vitro culture system. The
generated neurons could be a potential source of cell-based therapy to treat
stroke, and other neurodegenerative diseases.
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